论文部分内容阅读
目的:观察健康受试者单次服用八味健骨片临床治疗量(4片/人),安全大剂量(8片/人)后,Periplocin(杠柳毒苷)的药动行为。方法:筛选健康受试者18人,采用AccessImmunoassaySystemDigoxin试剂盒(免疫测定系统测定人血清Digoxin,简称A.I.S.D.法)测定了不同时刻血浆中Periplocin的浓度,根据血药浓度-时间数据,求得两个剂量组Periplocin药代动力学参数。结论:口服八味健骨片临床治疗量是安全的。
OBJECTIVE: To observe the pharmacokinetics of Periplocin after a single dose of Bawei Jiangu Tablets (4 tablets/person) and a safe large dose (8 tablets/person) in healthy subjects. METHODS: Eighteen healthy subjects were screened. The concentration of Periplocin in plasma at different time points was measured using the Access Immunoassay System Digoxin kit (Digoxin, referred to as the AISD method). Two doses were determined based on the plasma concentration-time data. Group Periplocin pharmacokinetic parameters. Conclusion: The clinical therapeutic amount of oral administration of Baweijiangu Tablet is safe.